CY1112817T1 - Ομοχαρριγκτονινη μονη ή συνδυασμενη με αλλους παραγοντες για χρηση στην αγωγη της χρονιας μυελογενους λευχαιμιας, ανθεκτικης ή μη ανεκτικης σε αναστολεις πρωτεϊνικης κινασης εκτος του sτi 571 - Google Patents

Ομοχαρριγκτονινη μονη ή συνδυασμενη με αλλους παραγοντες για χρηση στην αγωγη της χρονιας μυελογενους λευχαιμιας, ανθεκτικης ή μη ανεκτικης σε αναστολεις πρωτεϊνικης κινασης εκτος του sτi 571

Info

Publication number
CY1112817T1
CY1112817T1 CY20121100501T CY121100501T CY1112817T1 CY 1112817 T1 CY1112817 T1 CY 1112817T1 CY 20121100501 T CY20121100501 T CY 20121100501T CY 121100501 T CY121100501 T CY 121100501T CY 1112817 T1 CY1112817 T1 CY 1112817T1
Authority
CY
Cyprus
Prior art keywords
mylegenic
homoharrigonin
education
chronic
factors
Prior art date
Application number
CY20121100501T
Other languages
English (en)
Inventor
Julie Blanchard
François-Xavier Mahon
Frederick Maloisel
Jean-Pierre Robin
Hervé Maissonneuve
Original Assignee
IVAX International GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by IVAX International GmbH filed Critical IVAX International GmbH
Publication of CY1112817T1 publication Critical patent/CY1112817T1/el

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

Η παρούσα εφεύρεση αφορά μία μέθοδο αγωγής της χρόνιας μυελογενούς λευχαιμίας, μίας συγγενούς μυελοπολλαπλασιαστικής διαταραχής ή μίας Ph-θετικής οξείας λεμφοκυτταρικής λευχαιμίας σε ένα πάσχον ζώο, περιλαμβάνουσα: (a) την επιλογή ή τον εντοπισμό ενός ζώου πάσχοντος από χρόνια μυελογενή λευχαιμία ή μία συγγενή μυελοπολλαπλασιαστική διαταραχή και εμφανίζοντος αντοχή ή μη ανοχή στην αγωγή με SΤI571· και (b) τη χορήγηση στο ζώο ομοχαρριγκτονίνης. Σε μία προτιμώμενη πραγματοποίηση, το ζώο είναι ένα ανθρώπινο ον.
CY20121100501T 2001-09-05 2012-06-06 Ομοχαρριγκτονινη μονη ή συνδυασμενη με αλλους παραγοντες για χρηση στην αγωγη της χρονιας μυελογενους λευχαιμιας, ανθεκτικης ή μη ανεκτικης σε αναστολεις πρωτεϊνικης κινασης εκτος του sτi 571 CY1112817T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US31696701P 2001-09-05 2001-09-05
EP20090172828 EP2177223B9 (en) 2001-09-05 2002-09-05 Homoharringtonine alone or combined with other agents for use in treating chronic myelogenous leukemia resistant or intolerant to protein kinase inhibitors other than STI 571

Publications (1)

Publication Number Publication Date
CY1112817T1 true CY1112817T1 (el) 2016-02-10

Family

ID=23231501

Family Applications (2)

Application Number Title Priority Date Filing Date
CY20101100126T CY1109799T1 (el) 2001-09-05 2010-02-10 Αγωγη της χρονιας μυελογενους λευχαιμιας, ανθεκτικης ή μη ανεκτικης στο sti571, περιλαμβανουσα την ομοχαρριγκτονινη μονη ή συνδυασμενη με αλλους παραγοντες
CY20121100501T CY1112817T1 (el) 2001-09-05 2012-06-06 Ομοχαρριγκτονινη μονη ή συνδυασμενη με αλλους παραγοντες για χρηση στην αγωγη της χρονιας μυελογενους λευχαιμιας, ανθεκτικης ή μη ανεκτικης σε αναστολεις πρωτεϊνικης κινασης εκτος του sτi 571

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CY20101100126T CY1109799T1 (el) 2001-09-05 2010-02-10 Αγωγη της χρονιας μυελογενους λευχαιμιας, ανθεκτικης ή μη ανεκτικης στο sti571, περιλαμβανουσα την ομοχαρριγκτονινη μονη ή συνδυασμενη με αλλους παραγοντες

Country Status (13)

Country Link
US (1) US6987103B2 (el)
EP (2) EP2177223B9 (el)
JP (2) JP4794816B2 (el)
AT (2) ATE548041T1 (el)
AU (1) AU2002337410A1 (el)
CA (1) CA2459822C (el)
CY (2) CY1109799T1 (el)
DE (1) DE60234708D1 (el)
DK (2) DK1443933T3 (el)
ES (2) ES2383771T3 (el)
HK (2) HK1067562A1 (el)
PT (2) PT1443933E (el)
WO (1) WO2003020252A2 (el)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6613753B2 (en) * 2001-02-21 2003-09-02 Supergen, Inc. Restore cancer-suppressing functions to neoplastic cells through DNA hypomethylation
US6905669B2 (en) 2001-04-24 2005-06-14 Supergen, Inc. Compositions and methods for reestablishing gene transcription through inhibition of DNA methylation and histone deacetylase
US6998391B2 (en) * 2002-02-07 2006-02-14 Supergen.Inc. Method for treating diseases associated with abnormal kinase activity
AU2003291882A1 (en) * 2002-12-06 2004-06-30 Shire Biochem Inc. Pharmaceutical combinations and methods for the treatment of leukemia
US20050037992A1 (en) * 2003-07-22 2005-02-17 John Lyons Composition and method for treating neurological disorders
US20050059682A1 (en) * 2003-09-12 2005-03-17 Supergen, Inc., A Delaware Corporation Compositions and methods for treatment of cancer
US7250416B2 (en) * 2005-03-11 2007-07-31 Supergen, Inc. Azacytosine analogs and derivatives
US7700567B2 (en) 2005-09-29 2010-04-20 Supergen, Inc. Oligonucleotide analogues incorporating 5-aza-cytosine therein
US20070117776A1 (en) * 2005-11-04 2007-05-24 John Lyons Low Dose Therapy Of DNA Methylation Inhibitors
ES2400375T3 (es) * 2006-04-07 2013-04-09 Novartis Ag Combinación que comprende A) un compuesto de pirimidilaminobenzamida y B)un inhibidor de cinasa THR315LLE
EP2049096A4 (en) * 2006-08-02 2012-05-09 Univ South Florida METHOD FOR TREATING CELLS OF CHRONIC MYELOID LEUKEMIA
US20090068236A1 (en) * 2007-04-13 2009-03-12 Chemgenex Pharmaceuticals, Inc. Oral Cephalotaxine Dosage Forms
WO2009073885A1 (en) * 2007-12-07 2009-06-11 Chemgenex Pharmaceuticals, Inc. Leukemic stem cell ablation
JP5617175B2 (ja) 2008-04-17 2014-11-05 富士電機株式会社 ワイドバンドギャップ半導体装置とその製造方法
AU2012275190B2 (en) * 2011-06-29 2016-05-19 The Penn State Research Foundation Compositions, methods and kits for treating leukemia
KR102004559B1 (ko) 2011-08-30 2019-07-26 아스텍스 파마수티컬스, 인크. 데시타빈 유도체 제제
JP6768722B2 (ja) 2015-07-02 2020-10-14 大塚製薬株式会社 凍結乾燥医薬組成物
BR112020002280A2 (pt) 2017-08-03 2020-07-28 Otsuka Pharmaceutical Co., Ltd. composto farmacológico e métodos purificação do mesmo

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030148955A1 (en) * 1999-04-19 2003-08-07 Pluenneke John D. Soluble tumor necrosis factor receptor treatment of medical disorders

Also Published As

Publication number Publication date
EP2177223A2 (en) 2010-04-21
EP1443933A2 (en) 2004-08-11
WO2003020252A3 (en) 2003-06-19
US6987103B2 (en) 2006-01-17
CY1109799T1 (el) 2014-09-10
EP2177223B1 (en) 2012-03-07
JP2005508896A (ja) 2005-04-07
US20040019036A1 (en) 2004-01-29
DK2177223T3 (da) 2012-04-10
HK1143732A1 (en) 2011-01-14
PT2177223E (pt) 2012-05-23
EP2177223B9 (en) 2012-10-31
ATE548041T1 (de) 2012-03-15
ATE451106T1 (de) 2009-12-15
JP2009102408A (ja) 2009-05-14
HK1067562A1 (en) 2005-04-15
EP2177223A3 (en) 2010-05-19
JP4794816B2 (ja) 2011-10-19
DE60234708D1 (de) 2010-01-21
ES2334774T3 (es) 2010-03-16
CA2459822A1 (en) 2003-03-13
WO2003020252A2 (en) 2003-03-13
EP1443933B1 (en) 2009-12-09
CA2459822C (en) 2013-01-29
AU2002337410A1 (en) 2003-03-18
PT1443933E (pt) 2010-01-27
DK1443933T3 (da) 2010-01-25
ES2383771T3 (es) 2012-06-26

Similar Documents

Publication Publication Date Title
CY1112817T1 (el) Ομοχαρριγκτονινη μονη ή συνδυασμενη με αλλους παραγοντες για χρηση στην αγωγη της χρονιας μυελογενους λευχαιμιας, ανθεκτικης ή μη ανεκτικης σε αναστολεις πρωτεϊνικης κινασης εκτος του sτi 571
ATE412642T1 (de) Inhibitoren von p-38-kinase
DK1503788T3 (da) Behandling af alpha-galactosidase A-deficiens
BRPI0409701A (pt) ligantes de receptores de canabinóides e seus usos
BR0215115A (pt) Tratamento de perda muscular com moduladores de receptores de androgênio seletivos
DE60234269D1 (de) Substituierte aryl 1,4-pyrazin derivate
DK1355669T3 (da) Forbedret kognitiv træning
BRPI0407305A (pt) Ligantes do receptor de canabinóides e seus usos
DE60219961T8 (de) Behandlung von neurologischen funktionsstörungen mit fructopyranosesulfamaten und erythropoetin
DE60312736D1 (de) 1,2,4-triaminobenzolderivate zur behandlung von erkrankungen des zentralnervensystems
DE60304695D1 (de) 7-ARYLSULFONAMID-2,3,4,5-TETRAHYDRO-1H-BENZOiDöAZEPINE MIT 5-HT6 REZEPTOR AFFINITÄT ZUR BEHANDLUNG VON ZENTRALNERVENSYSTEMERKRANKUNGEN
DE602005007611D1 (de) Nahrungsmittelzusatz
ATE356994T1 (de) Screeningverfahren mit pim1-kinase oder pim3- kinase
ATE556707T1 (de) Phosphodiesesterase 4 inhibitoren zur behandlung eines kognitiven defizits
DK1397681T3 (da) Fremgangsmåde til identificering af midler til behandling af diabetes
NO20053903D0 (no) Nukleotidlipidesterderivater.
TR200101149T2 (tr) Dış retina bozukluklarının tedavisi.
DE60206289D1 (de) Verwendung von bibn4096 in kombination mit anderen migränemitteln zur behandlung von migräne
ATE517617T1 (de) Behandlung von parkinson erkrankung mit kape
DE69918145D1 (de) Verwendung von diltiazem zur behandlung von pathologien der netzhaut
DE60144383D1 (de) Methoden zur verminderung oder verhinderung von schmerzen mit spicamycin-derivaten
ATE291425T1 (de) R-eliprodil zur behandlung von glaucoma
BRPI0411382A (pt) derivados de 2-aminobenzoil
DE50106329D1 (de) Photodynamische behandlung und uv-b- bestrahlung einer thrombozyten-suspension
DE69920959D1 (de) Verwendung von riluzol zur behandlung von akustischen traumazuständen